Rafael Holdings Inc. Class B (RFL)
NYSE: RFLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RFL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $47.99M
- EPS (TTM)
- -$0.58
- Dividend yield
- None
- 52-week range
- 0.781 – 3.96
- Day range
- 0.8001 – 0.9691
- Volume / Avg
- 156.49K / 140.84K
- Beta
- —
- Shares outstanding
- 51.39M
- Next earnings
- Dec 10, 2026
52-week range
RFL stock today
On Nov 20, RFL ended the session at $0.9197, adding $0.0197 (2.19%), versus the S&P 500's 3.70% decline. At this level, RFL sits near the bottom of its 52-week range of $0.781 to $3.96: 76.8% below the high, set on Jul 1, 2026 and 17.8% above the low. RFL is down 22.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 25.8%.
Rafael has posted a net loss over the last twelve months (EPS of -$0.58), so its P/E ratio is not meaningful. The company is scheduled to report Oct/2026 results on Dec 10.
Summary generated from market data by MetaCap's automated system. Methodology
About Rafael
Company profileRafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Howard S. Jonas
- Headquarters
- Newark, NJ
- Employees
- 21
- IPO year
- 2018
- Website
- rafaelholdings.com
Financial highlights
Full financialsIn fiscal 2026, Rafael generated $874,000 in revenue, down 4.7% from fiscal 2025, its first annual decline since 2023. Rafael reported a net loss of $29.6 million, compared with a loss of $30.5 million a year earlier. Operating margin was -3822.5%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $874.00K | $917.00K | $637.00K | $279.00K | $410.00K |
| Growth | -4.69% | +43.96% | +128.32% | -31.95% | -48.88% |
| Net income | $-29.64M | $-30.52M | $-34.41M | $-1.88M | $-124.66M |
| EPS (diluted) | $-0.58 | $-1.04 | $-1.45 | $-0.08 | $-6.31 |
Earnings
Earnings history- Next report
- Dec 10, 2026
- Last reported (Jul/2026)
- Oct 29, 2026
- EPS actual vs est.
- $-0.18 vs —
RFL news
All RFL news- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFLPR Newswire
- Rafael Holdings, Inc. Submits NDA for Remibetadex Following Phase 3 TransportNPC StudyNasdaqRFL, BF.A
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFLPR Newswire
- Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswire
- Rafael Holdings Announces NDA Submission for Remibetadex and Reports Fiscal Year 2026 Financial ResultsNasdaq
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFLPR Newswire
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type CGlobeNewswire
Rafael peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HRTXHeron Therapeutics Inc. | 0.2525 | -4.39% | $48.04M | vs RFL |
| ONCYOncolytics Biotech Inc. | 0.3501 | -10.37% | $47.66M | vs RFL |
| NMADNomad Power Solutions Inc. | 2.56 | +13.53% | $47.15M | vs RFL |
| VRCAVerrica Pharmaceuticals Inc. | 2.74 | -5.03% | $47.07M | vs RFL |
| ACRVAcrivon Therapeutics Inc. | 1.15 | -17.86% | $49.35M | vs RFL |
| TNXPTonix Pharmaceuticals Holding Corp. | 2.38 | -6.67% | $46.25M | vs RFL |
| MISTMilestone Pharmaceuticals Inc. | 0.3711 | -7.06% | $46.20M | vs RFL |
| HOWLWerewolf Therapeutics Inc. | 0.9466 | -3.97% | $46.00M | vs RFL |
Indexes, lists and sector
Rafael stock FAQ
What is Rafael's stock price today?
RFL last traded at $0.9197 as of Nov 20, 4:00 PM EST, up 2.19% on the day. Prices are delayed at least 15 minutes.
Does Rafael pay a dividend?
No. Rafael does not currently pay a regular cash dividend.
When is Rafael's next earnings date?
Rafael is expected to report earnings on Thursday, December 10, 2026.
Who is Rafael's CEO?
Mr. Howard S. Jonas is the chief executive officer of Rafael Holdings Inc. Class B, which has about 21 employees.
Has RFL ever split its stock?
Yes. The most recent RFL stock split was a 1014-for-1000 split on May 9, 2025.
What is the RFL 52-week high?
The 52-week high for RFL is $3.96 and the 52-week low is $0.781. The stock is currently 76.8% below its high.